GRFS (Grifols) Moat Score: 7/10 (As of Jun. 26, 2026)


GRFS Grifols SA GRFS
84 GF Score
Price $7.36
GF Value $8.86
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Grifols Moat Score?

Grifols GRFS +2.08% 84 Moat Score is 7 as of Jun. 26, 2026. GuruFocus rates GRFS with a GF Score™ of 84/100 and a GF Value™ of $8.86 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,033 Drug Manufacturers companies, Grifols ranks better than 98.64% on this metric.

Grifols has the Moat Score of 7, which implies that the company might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

Grifols has Wide Moat: Grifols SA possesses a wide moat with strong market leadership in plasma-derived therapies, supported by valuable patents and regulatory barriers. Its extensive distribution network and brand strength further solidify its durable competitive advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Grifols might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

Grifols  (NAS:GRFS) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Grifols Moat Score Related Terms

GRFS vs LLY, JNJ, ABBV: Moat Score Comparison

For the Drug Manufacturers - General subindustry, Grifols's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Grifols Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grifols's Moat Score distribution charts can be found below:

* The bar in red indicates where Grifols's Moat Score falls into.


GRFS
84GF Score
Grifols SA GRFS
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 7 mean?
Grifols (GRFS) has a Moat Score of 7 as of Jun. 26, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Grifols ranks #14 out of 1033 companies in the Drug Manufacturers industry, placing it in the top 1.4%.
Is Grifols' Moat Score too high?
Grifols' current Moat Score is 7. Based on the distribution chart, Grifols ranks #14 out of 1033 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Grifols has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grifols' Moat Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Grifols ranks #14 out of 1033 companies for Moat Score. This places Grifols in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Grifols's current Moat Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grifols stock overvalued right now?
Based on GuruFocus' analysis, Grifols (GRFS) is currently considered Modestly Undervalued. The stock's GF Value™ is $8.86, compared to a current price of $7.36 — trading 17% below its estimated fair value. The current Moat Score is 7. Grifols' overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Grifols (GRFS), the current Moat Score is 7 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Grifols (GRFS) Overvalued in 2026?

Based on GuruFocus' analysis, Grifols stock appears to be undervalued. The current stock price of $7.36 is trading 17% below its estimated GF Value™ of $8.86. GuruFocus considers Grifols to be Modestly Undervalued.

Key valuation signals for GRFS:

  • Moat Score: 7
  • GF Value™: $8.86 vs. price of $7.36 (17% below fair value)
  • GF Score™: 84/100 with 6 warning signs

No single metric tells the full story. See the GRFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Grifols Business Description

Address Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
84GF Score

Get the complete analysis for GRFS

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.36
Price
$8.86
GF Value